Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jan 5, 2011

Premium

Former National Institutes of Health Director Elias Zerhouni will run global R&D at Sanofi-Aventis, replacing Marc Cluzel, who resigned. Since leaving NIH, Zerhouni has worked as a consultant for Sanofi-Aventis and he has served on the boards at Mayo Clinic and the Lasker Foundation.


Celera has tapped Alfred Merriweather to be senior vice president and CFO. Merriweather previously was executive vice president and CFO at Calypso Medical Technologies, and before that he served as CFO of Monogram Biosciences until it was bought by Laboratory Corporation of America in 2009. Merriweather also has been CFO of Symphonix Devices, Lipomatrix, and Laserscope.

Merriweather replaces Ugo DeBlasi, who left his position with the firm in November.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.